https://www.selleckchem.com/pr....oducts/nivolumab.htm
We compared the HP eradication rate according to treatment duration, CYP2C19 subtype and endoscopic diagnosis. We enrolled a total of 254 patients consisting of 127 patients in each treatment arm. The eradication rates of the control and test groups were 65.4% (82/127) and 74.8% (95/127), respectively, in the intention-to-treat analysis (P = .1). In the per-protocol analysis, 70.3% (83/118) and 82.6% (94/115) were eradicated in each group, which was statistically significant (P = .027). The CYP2C19 subtype was examined in 230 patients
Giống
Bình luận
Đăng lại
